Table 1.
Demographic and Clinical Parameters of Study Subjects, Overall and by Race/Ethnicity
| Variable | Total (n = 192) | White (n = 63) | Black (n = 40) | Asian (n = 30) | Hispanic (n = 51) | Native American (n = 8) | P |
|---|---|---|---|---|---|---|---|
| Age at treatment, y, | 50.65 ± 7.50 | 51.79 ± 5.99 | 52.60 ± 6.72 | 48.97 ± 10.31 | 49.00 ± 7.69 | 48.63 ± 5.85 | .02 |
| Sex | |||||||
| Female | 73 (38.0) | 29 (46.0) | 14 (35.0) | 9 (30.0) | 17 (33.3) | 4 (50.0) | .42 |
| Male | 119 (62.0) | 34 (54.0) | 26 (65.0) | 21 (70.0) | 34 (66.7) | 4 (50.0) | |
| HCV genotype | |||||||
| 1a | 85 (44.3) | 31 (49.2) | 18 (45.0) | 8 (26.7) | 23 (45.1) | 5 (62.5) | .02 |
| 1b | 76 (39.6) | 21 (33.3) | 19 (47.5) | 19 (63.3) | 15 (29.4) | 2 (25.0) | |
| Subtype unavailable | 31 (16.1) | 11 (17.5) | 3 (7.5) | 3 (10.0) | 13 (25.5) | 1 (12.5) | |
| Baseline fibrosis stage | |||||||
| 0 | 6 (3.1) | 3 (4.8) | 2 (5.0) | 0 | 1 (2.0) | 0 | .39 |
| 1 | 49 (25.5) | 21 (33.3) | 10 (25.0) | 4 (13.3) | 14 (27.5) | 0 | |
| 2 | 40 (20.8) | 12 (19.0) | 8 (20.0) | 9 (30.0) | 7 (13.7) | 4 (50.0) | |
| 3 | 37 (19.3) | 11 (17.5) | 11 (27.5) | 6 (20.0) | 8 (15.7) | 1 (12.5) | |
| Missing | 60 (31.3) | 16 (25.4) | 9 (22.5) | 11 (36.7) | 21 (41.2) | 3 (37.5) | |
| Log baseline viral load, IU/mL | 5.88 ± 0.56 | 5.96 ± 0.56 | 5.92 ± 0.50 | 5.75 ± 0.68 | 5.80 ± 0.56 | 6.02 ± 0.46 | .52 |
| Diabetes at baseline | 24 (12.5) | 3 (4.8) | 6 (15.0) | 5 (16.7) | 9 (17.6) | 1 (12.5) | .11 |
| SVR | 99 (51.6) | 33 (52.4) | 16 (40.0) | 21 (70.0) | 25 (49.0) | 4 (50.0) | .09 |
| IL28B genotype | |||||||
| CC | 71 (40.0) | 26 (41.3) | 4 (10.0) | 20 (66.7) | 17 (33.3) | 4 (50.0) | <.001 |
| CT or TT (non-CC) | 121 (60.0) | 37 (58.7) | 36 (90.0) | 10 (33.3) | 34 (66.7) | 4 (50.0) | |
Data are mean ± SD or no. (%) of subjects.
Abbreviations: HCV, hepatitis C virus; SVR, sustained virologic response.